IMC-1 is a combination treatment that is designed to suppress this suspected virus and thus alleviate fibromyalgia symptoms. IMC plans to start a Phase 3 randomized double-blinded multi-center factorial pivotal trial using an improved IMC-1 later this year.
Https Ir Virios Com Sec Filings All Sec Filings Content 0001104659 20 129640 0001104659 20 129640 Pdf
IMC-1 oral medication proves highly effective at reducing pain and other symptoms of fibromyalgia FM in patients in a recent clinical trial.
Imc 1 phase 3 clinical trial. IMCgp100 is to be administered at 20 mcg cycle 1 day1 then 30 mcg cycle 1 day 8 then 68 mcg cycle 1 day 15 and weekly thereafter by IV infusion over 15 minutes until confirmed disease progression or unacceptable toxicity. Key points of phase III clinical trials. A phase I trial of escalating doses of cixutumumab IMC-A12 and sorafenib in the treatment of advanced hepatocellular carcinoma Cancer Chemother Pharmacol.
Condition or disease Interventiontreatment. According to this design it proceeds with cohort of 3 patients who are treated at a starting dose that is considered to be safe based on extrapolation from animal toxicological data. IMC-1 is a novel combination oral medicine designed to treat HSV-1 a condition that may be.
A Phase 1 Open-Label Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety Tolerability Activity and Pharmacokinetics of REGN3767 anti-LAG-3 mAb Administered Alone or in Combination with REGN2810 anti-PD-1 mAb in. Quadruple Participant Care Provider Investigator Outcomes Assessor Primary Purpose. The IMC-C103C-101 Phase 12 study will be evaluated in patients with metastaticunresectable tumors which include select Advanced Solid Tumors and will be conducted in two phases.
Interventional Clinical Trial Estimated Enrollment. A phase III first-in-human study of a novel anti-MAGE-A4 TCRanti-CD3 bispecific IMC-C103C as monotherapy and in combination with atezolizumab in HLA-A0201-positive patients with MAGE-A4-positive advanced solid tumors IMC-C103C-101. Full Title A Phase 12 First-in-human Study of the Safety and Efficacy of IMC-C103C as a Single Agent and in Combination with Atezolizumab in HLA-A0201-positive Patients with Advanced MAGE-A4-positive Cancer Purpose The purpose of this study is to find the highest dose of the investigational drug IMC-C103C that can be given alone and in combination with atezolizumab.
Pridgen expects even better results from next years phase III trial because it will use the dosage hes been perfecting in his practice for the past six years. 33 design is the most commonly used design in conducting phase I cancer Clinical trials. Phase III clinical trials are more likely to be offered in local community hospitals and doctors offices.
These studies are often done in many places across the country or even around the world at the same time. About Innovative Med Concepts. Suppressing latent herpes viruses may significantly improve fibromyalgia related symptoms.
Actual Primary Completion Date. A Multicenter Multinational Randomized Double-Blind Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients With HER2-Negative Unresectable Locally-Recurrent or Metastatic Breast Cancer. To identify the MTD andor RP2D of IMC-C103C as a single agent administered Q1W Arm A1 and administered Q1W in combination with Q3W atezolizumab Arm A2.
Side effects were low with more patients from the placebo group dropping out of the trial due to adverse reactions than those taking IMC-1. In a phase 1 clinical trial the tolerability and safety of the new drug is studied usually in a small number of healthy volunteers. Most phase III clinical trials include a large number of patients at least several hundred.
Actual Study Start Date. Phase 3 clinical trials follow phase 1 and 2 clinical trials. To assess the preliminary anti-tumor activity of IMC-F106C in up to 4 indications as a single agent administration.
This is a Phase III randomized multicenter double-blind placebo controlled trial evaluating the safety and efficacy of paclitaxel plus ramucirumab IMC-1211B drug product DP compared to paclitaxel plus placebo. To identify the Maximum Tolerated Dose MTD andor Recommended Phase 2 dose RP2D of IMC-F106C as a single agent Arm A and administered in combination with Checkpoint Inhibitors Arm B. We are currently meeting the development requirements to begin.
